Read by QxMD icon Read


Rebecca Harris, David J Harman, Timothy R Card, Guruprasad P Aithal, Indra Neil Guha
As of 2016, there is no evidence-based pathway to stratify the risk of chronic liver disease in a general population setting. Non-invasive tests of liver fibrosis might provide a mechanism for earlier diagnosis. These tests have been extensively validated in the hospital setting but their performance in a general population setting is unclear. We did a systematic review of non-invasive tests used to stratify patients at risk of clinically significant liver disease in a general population setting and report the prevalence of chronic liver disease as defined by these tests...
April 2017: Lancet. Gastroenterology & Hepatology
Amyna Fidai, Frederic Dallaire, Nanette Alvarez, Yvonne Balon, Robin Clegg, Michael Connelly, Frank Dicke, Deborah Fruitman, Joyce Harder, Kimberley Myers, David J Patton, Tim Prieur, Erika Vorhies, Robert P Myers, Steven R Martin, Steven C Greenway
Fontan-associated liver disease (FALD) is a serious complication related to the chronically elevated venous pressure and low cardiac output of this abnormal circulation. However, diagnostic markers for this condition are limited. We hypothesized that specific tests for fibrosis developed for other chronic liver diseases would identify a higher prevalence of FALD than ultrasound and standard laboratory tests and that identified abnormalities would correlate with time post-Fontan. In this cross-sectional study, we assessed 19 children (average age 8...
2017: Frontiers in Cardiovascular Medicine
Pierre Poinsot, Sophie Collardeau Frachon, Lioara Restier, André Sérusclat, Mathilde Di Filippo, Sybil Charrière, Philippe Moulin, Alain Lachaux, Noel Peretti
BACKGROUND: The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset LALD) is a rare genetic disease. Children present severe fatty liver disease with early cirrhosis. Before enzyme replacement therapy, statins were the standard treatment to improve the severe dyslipidemia. However, late-onset LALD should be considered as a systemic metabolic disease: chronic hyper-low-density lipoprotein and hypo-high-density lipoprotein cholesterolemia induces early atherosclerosis in addition to the liver morbidity...
January 2017: Journal of Clinical Lipidology
Cosmin Sebastian Voican, Alexandre Louvet, Jean-Baptiste Trabut, Micheline Njiké-Nakseu, Sébastien Dharancy, Andrea Sanchez, Marion Corouge, Karima Lamouri, Amandine Lebrun, Axel Balian, Sophie Prévot, Mounia Lachgar, Sophie Maitre, Hélène Agostini, Philippe Mathurin, Gabriel Perlemuter, Sylvie Naveau
BACKGROUND&AIMS: The reliability of transient elastography (TE) to assess liver fibrosis is insufficiently validated in alcoholic liver disease (ALD). We aimed to validate the diagnostic utility of TE for liver fibrosis in patients with excessive alcohol consumption and evaluate whether Fibrotest(®) adds diagnostic value relative to or in combination with TE. METHODS: We conducted a multicenter prospective study on a total of 217 heavy drinkers with high serum aminotransferase levels...
April 7, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
Anders Boyd, Julie Bottero, Patrick Miailhes, Caroline Lascoux-Combe, Hayette Rougier, Pierre-Marie Girard, Lawrence Serfaty, Karine Lacombe
INTRODUCTION: Long-term tenofovir disoproxil fumarate (TDF) use has been associated with significant regression of liver fibrosis during hepatitis B virus (HBV) mono-infection, yet little is known during HIV-HBV coinfection. The aim of this study was to evaluate the evolution of liver fibrosis and its determinants in TDF-treated coinfected patients. METHODS: In this prospective cohort study, 167 HIV-HBV-infected patients initiating TDF-containing antiretroviral therapy were included...
February 28, 2017: Journal of the International AIDS Society
I G Bakulin, Yu G Sandler, E V Vinnitskaya, V A Keiyan, S V Rodionova, D L Rotin
AIM: To estimate the incidence of hepatic steatosis (HS) and liver fibrosis (LF) in patients with diabetes mellitus (DM), by applying the noninvasive techniques of liver fibroelastometry (LFE) and a battery of fibrotests (FTs); to determine their diagnostic value and to identify factors influencing the development of LF. SUBJECTS AND METHODS: A comprehensive examination was made in 82 diabetic patients (mean age, 56.7±12.7 years; p=0.033). The data were statistically evaluated using ROC curve analysis, correlation and single-factor analyses of variance, and multiple logistic regression analysis...
2017: Terapevticheskiĭ Arkhiv
Thierry Poynard, Tam Pham, Hugo Perazzo, Mona Munteanu, Elena Luckina, Djamel Elaribi, Yen Ngo, Luminita Bonyhay, Noemie Seurat, Muriel Legroux, An Ngo, Olivier Deckmyn, Dominique Thabut, Vlad Ratziu, Olivier Lucidarme
BACKGROUND AND AIMS: Real-time shear wave elastography (2D-SWE) is a two-dimensional transient elastography and a competitor as a biomarker of liver fibrosis in comparison with the standard reference transient elastography by M probe (TE-M). The aims were to compare several criteria of applicability, and to assess inflammation and steatosis impact on elasticity values, two unmet needs. METHODS: We took FibroTest as the fibrosis reference and ActiTest and SteatoTest as quantitative estimates of inflammation and steatosis...
2016: PloS One
M Munteanu, D Tiniakos, Q Anstee, F Charlotte, G Marchesini, E Bugianesi, M Trauner, M Romero Gomez, C Oliveira, C Day, J-F Dufour, S Bellentani, Y Ngo, S Traussnig, H Perazzo, O Deckmyn, P Bedossa, V Ratziu, T Poynard
BACKGROUND: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. AIMS: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. METHODS: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium...
October 2016: Alimentary Pharmacology & Therapeutics
Bassem Matta, Tzu-Hao Lee, Keyur Patel
Patients with HIV have a proclivity to develop liver fibrosis, especially when associated with other conditions such as HCV, HBV, and NAFLD. Identifying HIV-infected patients with significant fibrosis or cirrhosis plays an important role in clinical and therapeutic decision-making. Liver biopsy is currently considered as the gold standard for fibrosis assessment but carries many shortcomings (cost, invasiveness, complications, false negative rate of 20 %). Multiple non-invasive methods of liver fibrosis assessment have been developed, but not all have been studied in HIV-infected individuals...
October 2016: Current HIV/AIDS Reports
Rénovat Ntagirabiri, Belyse Munezero, Caritas Nahimana, Evariste Ndabaneze
INTRODUCTION: Hepatitis B virus infection (VHB) is a serious condition which can lead to serious complications, such as cirrhosis and hepato-cellular carcinoma (HCC). HBV genotypes greatly influence its evolution and the effectiveness of treatment. The aim was to evaluate the HBV genotypes and the evolutionary pathways of chronic HBsAG patients. METHODS: A cross-sectional study was conducted at the University Hospital of Kamenge and at the Digestive and liver diseases Center "CEMADIF" between June 2013 and Mai 2014...
2016: Pan African Medical Journal
Marco Merli, Laura Galli, Antonella Castagna, Stefania Salpietro, Nicola Gianotti, Emanuela Messina, Andrea Poli, Giulia Morsica, Sabrina Bagaglio, Massimo Cernuschi, Alba Bigoloni, Caterina Uberti-Foppa, Adriano Lazzarin, Hamid Hasson
We determined the diagnostic accuracy and optimal cut off of three indirect fibrosis biomarkers (APRI, FIB-4, Forns) compared with liver stiffness (LS) for the detection of liver cirrhosis in HIV/HCV-coinfected patients. An observational retrospective study on HIV/HCV-coinfected patients with concomitant LS measurement and APRI, FIB-4 and Forns was performed. The presence of liver cirrhosis was defined as a LS ≥13 KPa. The diagnostic accuracy and optimal cut-off values, compared with LS categorization (<13 vs ≥13 KPa), were determined by receiver operating characteristics (ROC) curves...
2016: New Microbiologica
Jérôme Boursier, Julien Vergniol, Anne Guillet, Jean-Baptiste Hiriart, Adrien Lannes, Brigitte Le Bail, Sophie Michalak, Faiza Chermak, Sandrine Bertrais, Juliette Foucher, Frédéric Oberti, Maude Charbonnier, Isabelle Fouchard-Hubert, Marie-Christine Rousselet, Paul Calès, Victor de Lédinghen
BACKGROUND & AIMS: NAFLD is highly prevalent but only a small subset of patients develop advanced liver fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis tests and liver stiffness measurement (LSM) by FibroScan for the diagnosis of liver fibrosis and the evaluation of prognosis in NAFLD. METHODS: Diagnostic accuracy was evaluated in a cross-sectional study including 452 NAFLD patients with liver biopsy (NASH-CRN fibrosis stage), LSM, and eight blood fibrosis tests (BARD, NAFLD fibrosis score, FibroMeter(NAFLD), aspartate aminotransferase to platelet ratio index (APRI), FIB4, FibroTest, Hepascore, FibroMeter(V2G))...
September 2016: Journal of Hepatology
Sara Bignulin, Edmondo Falleti, Sara Cmet, Dario Cappello, Annarosa Cussigh, Ilaria Lenisa, Denis Dissegna, Fabio Pugliese, Cinzia Vivarelli, Carlo Fabris, Carlo Fabris, Pierluigi Toniutto
UNLABELLED:  Background and rationale. Acoustic radiation force impulse (ARFI) is a non-invasive tool used in the evaluation of liver fibrosis in HCV positive immune-competent patients. This study aimed to assess the accuracy of ARFI in discriminating liver transplanted patients with different graft fibrosis severity and to verify whether ARFI, eventually combined with non-invasive biochemical tests, could spare liver biopsies. This prospective study included 51 HCV positive liver transplanted patients who consecutively underwent to annual liver biopsy concomitantly with ARFI and blood chemistry tests measurements needed to calculate several non-invasive liver fibrosis tests...
March 2016: Annals of Hepatology
Cristina Stasi, Stefano Milani
The assessment of the fibrotic evolution of chronic hepatitis has always been a challenge for the clinical hepatologist. Over the past decade, various non-invasive methods have been proposed to detect the presence of fibrosis, including the elastometric measure of stiffness, panels of clinical and biochemical parameters, and combinations of both methods. The aim of this review is to analyse the most recent data on non-invasive techniques for the evaluation of hepatic fibrosis with particular attention to cost-effectiveness...
January 28, 2016: World Journal of Gastroenterology: WJG
Monika Gudowska, Ewa Wojtowicz, Bogdan Cylwik, Ewa Gruszewska, Lech Chrostek
BACKGROUND: The diagnosis of alcoholic liver diseases is based on the history of alcohol abuse, clinical evidence of liver disease and laboratory abnormalities. The new non-invasive biomarkers have higher sensitivity to quantify and predict steatosis and fibrosis than ultrasonography. OBJECTIVES: The aim of this study was to evaluate the prevalence of liver diseases in alcoholics by means of FibroMax. MATERIAL AND METHODS: A total of 142 consecutive alcoholics were enrolled in the study...
September 2015: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
Jieyao Cheng, Jinlin Hou, Huiguo Ding, Guofeng Chen, Qing Xie, Yuming Wang, Minde Zeng, Xiaojuan Ou, Hong Ma, Jidong Jia
BACKGROUND AND AIMS: Noninvasive models have been developed for fibrosis assessment in patients with chronic hepatitis B. However, the sensitivity, specificity and diagnostic accuracy in evaluating liver fibrosis of these methods have not been validated and compared in the same group of patients. The aim of this study was to verify the diagnostic performance and reproducibility of ten reported noninvasive models in a large cohort of Asian CHB patients. METHODS: The diagnostic performance of ten noninvasive models (HALF index, FibroScan, S index, Zeng model, Youyi model, Hui model, APAG, APRI, FIB-4 and FibroTest) was assessed against the liver histology by ROC curve analysis in CHB patients...
2015: PloS One
Thierry Poynard, Olivier Deckmyn, Mona Munteanu, Yen Ngo, Fabienne Drane, Jean Marie Castille, Chantal Housset, Vlad Ratziu
BACKGROUND: Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for a fibrosis score to support DDA reimbursement and a screening strategy, such as the USA baby boomer campaign, should lead to an increased awareness of liver disease severity. OBJECTIVE: To compare the awareness of liver disease severity between the USA and France, two countries with similar access to hepatitis C virus (HCV) and hepatitis B virus (HBV) treatments, similar rules for treatment reimbursement and similar availability of validated fibrosis tests, but with different policies, as France has no screening...
December 23, 2015: BMJ Open
S Brener
BACKGROUND: Liver fibrosis is a sign of advanced liver disease and is often an indication for treatment. The current standard for diagnosing liver fibrosis and steatosis is biopsy, but noninvasive alternatives are available; one of the most common is transient elastography (FibroScan). OBJECTIVES: The objective of this analysis was to assess the diagnostic accuracy and clinical utility of transient elastography alone for liver fibrosis and with controlled attenuation parameter (CAP) for steatosis in patients with hepatitis C virus, hepatitis B virus, nonalcoholic fatty liver disease, alcoholic liver disease, or cholestatic diseases...
2015: Ontario Health Technology Assessment Series
Chunyan Wang, Xiaojing Cheng, Chao Meng, Wei Lu
OBJECTIVE: To determine the diagnostic value of FibroTest (FT) for liver fibrosis in patients with chronic hepatitis B (CHB). METHODS: One hundred and forty-two patients with CHB were tested for the following five indicators: alpha2-microglobulin (a2-MG), haptoglobin (Hp), gamma-glutarnyl peptidase (GGT), total bilirubin (TBIL), and apolipoprotein A1 (ApoA1). The resultant data, along with the age and sex of the patients, were put into an algorithm to compute the final results of the FT...
October 2015: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Ingrid Jullian-Desayes, Renaud Tamisier, Jean-Pierre Zarski, Judith Aron-Wisnewsky, Sandrine H Launois-Rollinat, Candice Trocme, Patrick Levy, Marie Joyeux-Faure, Jean-Louis Pepin
BACKGROUND AND OBJECTIVE: Obstructive sleep apnoea (OSA) could be an independent risk factor for non-alcoholic fatty liver disease (NAFLD) occurrence and progression. The impact of continuous positive airway pressure (CPAP) treatment on non-invasive markers of NAFLD has not been studied. The aim of this study was to evaluate the effect of 6-12 weeks of effective CPAP on the FibroMax test (comprising components including the SteatoTest, NashTest and FibroTest) through three randomized sham controlled studies...
February 2016: Respirology: Official Journal of the Asian Pacific Society of Respirology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"